drugset / Trial / NCT00038948

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

NCT00038948

Phase 3 Completed 830 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.

Timeline

Start
2002-01
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide
Comparator Sirolimus Small molecule
Comparator Tacrolimus Small molecule

Indications

No indication recorded.